Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

Diabetes mellitus is a group of diseases defined by persistent hyperglycaemia. Type 2
diabetes, the most prevalent form, is characterised initially by impaired insulin sensitivity and …

The incretin effect describes the phenomenon whereby oral glucose elicits higher insulin
secretory responses than does intravenous glucose, despite inducing similar levels of …

We report the discovery and translational therapeutic efficacy of a peptide with potent,
balanced co-agonism at both of the receptors for the incretin hormones glucagon-like …

The incretin effect, the amplification of insulin secretion occurring when glucose is taken in
orally as compared to infused intravenously, is one of the factors that help the body to …

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …

Postprandial glucose, together with related hyperinsulinemia and lipidaemia, has been
implicated in the development of chronic metabolic diseases like obesity, type 2 diabetes …

Insulin remains indispensable in the treatment of diabetes, but its use is hampered by its
narrow therapeutic index. Although advances in peptide chemistry and recombinant DNA …

Type 2 diabetes mellitus is a growing global public health problem, the prevalence of which
is projected to increase in the succeeding decades. It is potentially associated with many …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …